This growth is primarily driven by the expanding application of ADCs in earlier lines of therapy and neoadjuvant settings, as well as the advancement of novel targets such as B7-H3 and DLL3 in refractory cancers [313, 335, 336]. The gene discussed is CD276; the disease is cancer.